We are planning a big promotion for welcome May Day, and provide the one-stop service

  • May Day,one-stop service,Gold Sponsor,chemical business


We are planning a big promotion for welcomingMay Day, and provide the one-stop service, which can help you to make chemicalbusiness easily. An event named " Gold Sponsor Special Promotion" isbeing introduced.

 

What can you do with RMB 3000 here? You canbe our Gold Sponsor with only RMB 3000.

Right here, RMB 3000= ChemCD website service + Professional chemical enterprise website.



Introduction of activities in details:

1. ChemCD website service includes:

(1)You will have the privilege of displaying your product in the forward position of our website. which will make you get more chances for customers’ inquiries. And the value of it is RMB3000 per year.

(2)For enhancing the visibility of your company, the text advertising will be handseled, the value of it is RMB1500 per year.

Note: The validity of ChemCD site service isone year, the cost of these services are included in all of RMB3000. After thatperiod you do not have to pay any fee, if necessary, you can continue to buyone.

 

2. Professional chemical enterprise websiteincludes:

(1)Get a website worth RMB 2500, and latter can be upgraded to HTML5.

(2)Get an international top-leveldomain name, the value of it is RMB130 / year;

  (3)   Free unlimited bandwidth overseas filing room! The value is RMB 2000/ year (youcan select  a node, for example, if mostof your customers come from Japan,we can put the space and the database in Japanor Singapore,which will ensure the access speed of your clients )

 (4)  Geta second-level domain.

 (5)  Getan enterprise post office.

Note: The validity of Professional chemical enterprise website services is one year, the cost of these services are included in all of RMB3000. After that period, you need to pay for RMB 1500 ofthe website maintenance fees annually.

 

After the event, all the services restorethe original price. During the event, if you purchase three years of service inone time , you will get one more year of our service, so your service will beextended to four years!

 

Limited to 1000 copies! Purchase now, firstcome and first served! Unlimited service, and limited quantity, please buy itand treasure.

 

Event Time: From Apr 30th, 2014to May 30th, 2014

 

Contact:

Tel: 86-571-81025280

E-mail:service@chemcd.com

QQ:320204646



This link: http://www.chemcd.com/news/29.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source



This link:http://www.chemcd.com/news/29.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus

Categories

Related News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.